US Patent

US10172802 — Oral pharmaceutical dosage forms of budesonide

Method of Use · Assigned to Sun Pharmaceutical Industries Ltd · Expires 2036-09-09 · 10y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects novel oral sustained release pharmaceutical dosage forms of budesonide for treating Crohn's disease.

USPTO Abstract

The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease.

Drugs covered by this patent

Pulmicort Respules (BUDESONIDE) · AstraZeneca K.K.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2554`	—	Pulmicort Respules
`U-2554`	—	Pulmicort Respules

Patent Metadata

Patent number: US10172802
Jurisdiction: US
Classification: Method of Use
Expires: 2036-09-09
Drug substance claim: No
Drug product claim: No
Assignee: Sun Pharmaceutical Industries Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.